Whether mTOR inhibitors are safe and effective in patients with FCD has been addressed in individual case reports [203, 204], two completed small trials (14 patients in [205], 16 patients in [206]) and one open label trial [207]. Here, MTOR is linked to fleck corneal dystrophy.